Xi'an DELI Biochemical Successfully Concludes CPHI China 2026, Showcasing Cyclodextrins and Pharmaceutical APIs
Shanghai, China – June 2026 – Xi'an DELI Biochemical Industry Co., Ltd. successfully concluded its participation in CPHI China 2026, one of the pharmaceutical industry's most influential international exhibitions. Held in Shanghai, the event brought together pharmaceutical manufacturers, formulation scientists, distributors, research organizations, and healthcare professionals from around the world, providing an excellent platform for business networking, technical exchange, and global collaboration.
Throughout the exhibition, DELI welcomed visitors from Asia, Europe, North America, South America, the Middle East, and Africa. Customers visited the company's booth to discuss pharmaceutical excipients, active pharmaceutical ingredients (APIs), formulation development, regulatory requirements, quality standards, and long-term supply partnerships.
At CPHI China 2026, DELI presented its expanding portfolio of pharmaceutical excipients and active pharmaceutical ingredients designed to support modern drug development.
The company's featured pharmaceutical excipients included:
These products are widely used to improve drug solubility, stability, bioavailability, and drug delivery performance across injectable, oral, ophthalmic, and specialty pharmaceutical formulations.
In addition to excipients, DELI also showcased several pharmaceutical APIs, including:
The diversified product portfolio attracted strong interest from pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), distributors, and formulation specialists looking for reliable manufacturing partners.
As pharmaceutical research continues to advance, the number of poorly water-soluble drug candidates is steadily increasing. Improving solubility, stability, and bioavailability has become a key challenge for formulation scientists worldwide.
During the exhibition, DELI's technical team shared application experience and technical knowledge on cyclodextrin-based excipients, particularly Hydroxypropyl Betadex (HPBCD) and Betadex Sulfobutyl Ether Sodium (SBECD). Visitors discussed their applications in injectable formulations, oral dosage forms, ophthalmic preparations, and other advanced drug delivery systems.
Many customers also expressed interest in Icodextrin for specialized pharmaceutical applications, while DELI's API portfolio—including Vonoprazan Fumarate, Glucosamine Sulfate Sodium Chloride, and Menatetrenone—generated productive discussions regarding market demand, product quality, and future cooperation opportunities.
With more than 27 years of manufacturing experience, Xi'an DELI Biochemical has established itself as a trusted supplier of pharmaceutical excipients and APIs.
The company operates a dedicated manufacturing facility equipped with advanced production technology and comprehensive quality management systems. Every production batch undergoes rigorous analytical testing to ensure consistent quality, reliable performance, and compliance with pharmaceutical standards.
DELI continues to invest in manufacturing capabilities, process optimization, and quality assurance to support customers from early-stage research and formulation development through commercial production.
Stable production capacity, consistent batch quality, and responsive technical support remain the foundation of DELI's long-term partnerships with customers around the world.
One of the highlights of CPHI China 2026 was the opportunity to meet customers face-to-face.
Throughout the three-day exhibition, DELI's sales and technical teams held numerous discussions with existing customers and first-time visitors regarding product applications, formulation challenges, technical documentation, sample evaluation, regulatory requirements, and future business cooperation.
These conversations provided valuable insights into the evolving needs of the global pharmaceutical industry while strengthening DELI's relationships with partners across different international markets.
The company also exchanged ideas with customers on future product development projects, customized technical support, and long-term supply strategies, laying the foundation for new collaborations following the exhibition.
At DELI, customer support extends far beyond product supply.
The company works closely with pharmaceutical partners by providing technical consultation, formulation support, regulatory documentation, analytical assistance, and responsive customer service throughout every stage of product development.
Whether customers are evaluating Hydroxypropyl Betadex (HPBCD) for solubility enhancement, Betadex Sulfobutyl Ether Sodium (SBECD) for injectable formulations, Icodextrin for specialized pharmaceutical applications, or APIs such as Vonoprazan Fumarate, Glucosamine Sulfate Sodium Chloride, and Menatetrenone, DELI is committed to delivering reliable products supported by professional technical expertise.
The successful conclusion of CPHI China 2026 marks another important milestone in DELI's international development.
Following the exhibition, the DELI team will continue following up with customers, arranging product samples, providing technical documentation, and supporting formulation development projects around the world.
Our next international exhibition will be CPHI Milan 2026, and we warmly invite pharmaceutical manufacturers, distributors, formulation scientists, and industry partners to visit Xi'an DELI Biochemical at Booth 1H24.
At CPHI Milan, DELI will continue showcasing its comprehensive portfolio of pharmaceutical excipients and APIs, including Hydroxypropyl Betadex (HPBCD), Betadex Sulfobutyl Ether Sodium (SBECD), Icodextrin, Glucosamine Sulfate Sodium Chloride, Vonoprazan Fumarate, and Menatetrenone. Our team looks forward to discussing your formulation challenges, product requirements, and future cooperation opportunities.
Xi'an DELI Biochemical sincerely thanks every customer, distributor, partner, and industry professional who visited our booth during CPHI China 2026.
Your trust, valuable discussions, and continued support inspire us to keep delivering high-quality pharmaceutical excipients, APIs, and professional technical services to customers worldwide.
If we did not have the opportunity to meet in Shanghai, we would be delighted to welcome you at CPHI Milan 2026, Booth 1H24. We look forward to seeing you in Milan and exploring new opportunities for cooperation.
Xi'an DELI Biochemical Industry Co., Ltd. is a professional manufacturer specializing in pharmaceutical excipients, cyclodextrin derivatives, and active pharmaceutical ingredients (APIs). With over 27 years of manufacturing experience, the company serves pharmaceutical customers worldwide with reliable products, consistent quality, and responsive technical support.
DELI's core product portfolio includes Hydroxypropyl Betadex (HPBCD), Betadex Sulfobutyl Ether Sodium (SBECD), Icodextrin, Glucosamine Sulfate Sodium Chloride, Vonoprazan Fumarate, and Menatetrenone (Vitamin K2).
Supported by advanced manufacturing technology, strict quality management systems, and dependable production capacity, DELI is committed to helping pharmaceutical companies develop safe, effective, and innovative medicines. As a long-term partner to the global pharmaceutical industry, DELI continues to provide high-quality products, comprehensive technical support, and reliable supply solutions for customers around the world.
